kabutan

RaQualia Pharma surges as licensee presents tegoprazan phase 3 trial data at international conference

Thu May 7, 2026 9:37 am JST Catalyst

RaQualia Pharma Inc. <4579> continued to rise sharply. Before the market opened today, the company announced that data from a phase 3 clinical trial of the gastric acid secretion inhibitor "tegoprazan" for erosive esophagitis (EE) was presented orally at Digestive Disease Week 2026 (DDW 2026), one of the world's largest international conferences in the field of gastroenterology, held in the United States from May 2 to 5, which has attracted buying interest.

The presentation was made by licensee HK inno.N Corp. of South Korea and sublicensee Sebela Pharmaceuticals Inc. of the United States, reporting that the drug demonstrated statistical superiority over the comparator in healing and maintaining healing of EE across all severity grades. In particular, the superiority over the comparator was shown to be more pronounced in patients with the most severe grade.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles